Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31206751 | 1.00 | CYP3A4 (0.37) | CYP3A4ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL29759333 | 0.79 | ALDH1A1 (0.42) | CYP3A4ALDH1A1TP53TDP1POLB | |
| SCHEMBL4663299 | 0.79 | ALDH1A1 (0.42) | CYP3A4ALDH1A1TP53TDP1POLB | |
| SCHEMBL5746102 | 0.77 | ALDH1A1 (0.40) | CYP3A4ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL30421541 | 0.77 | ALDH1A1 (0.40) | CYP3A4ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL1868968 | 0.77 | GAA (0.40) | TDP1MEN1HTTKMT2AGAA | |
| SCHEMBL3886713 | 0.77 | POLB (0.53) | CYP3A4ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL11985860 | 0.77 | ALDH1A1 (0.32) | ALDH1A1POLBMAPK1SMN1; SMN2 | |
| SCHEMBL29513014 | 0.77 | POLB (0.53) | CYP3A4ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL4596400 | 0.77 | TDP1 (0.34) | TDP1MEN1HTTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024025896-A2 | PROTEIN KINASE C (PKC) THETA INHIBITOR COMPOUNDS | EVOMMUNE, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-110615787-A | Platinum complex, application thereof and organic photoelectric device comprising platinum complex | 南京佳诺霖光电科技有限公司 | 2019-12-27 | — | — | CN | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| CN-101600715-A | Compound with angiotensin-ii receptor antagonistic action and PPAR γ activating activities | PFIZER PROD INC (US) | 2009-12-09 | — | — | CN | disclosed |
| EP-2125806-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | Pfizer Products Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008084303-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084303-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029710-A1 | COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES | AGTR2, AGTR1, AGT | CYP3A4 1644/4885ALDH1A1 1739/4885TSHR 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.